TMA and race effect on survival among patients who received a transplant. Kaplan-Meier survival curves (total n = 333). HSCT survival is inferior in (A) HSCT patients who developed TMA (63% vs 85% 1-year overall survival [OS] and 52% vs 83% 3-year OS; P = .0001) and in (B) nonwhite HSCT recipients (56% vs 81% 1-year OS and 56% vs 75% 3-year OS; P = .0009). (C-D) Effect of TMA and race combined on HSCT survival. (C) Race did not have significant influence on survival in HSCT recipients without TMA (73% vs 87% 1-year OS and 73% vs 84% 3-year OS; P = .12). (D) Nonwhite HSCT recipients who developed TMA had significantly inferior survival compared with whites who developed TMA (37% vs 69% 1-year OS and 37% vs 55% 3-year OS, P = .04).